ADIL — Adial Pharmaceuticals Share Price
Last Trade - 00:00Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of medications for the treatment of addictions and related disorders. Its lead investigational drug product is AD04. AD04 is being developed for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist. AD04 is being designed to be used for the treatment of other addictive disorders, such as opioid use disorder, obesity, smoking, and other drug addictions.
Directors
- William Stilley PRE (53)
- Kevin Schuyler (51)
- Joseph Truluck CFO (42)
- Bankole Johnson OTH (60)
- J. Kermit Anderson (71)
- Robertson Gilliland (39)
- Tony Goodman (56)
- James Newman (77)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- October 5th, 2017
- Public Since
- July 27th, 2018
- No. of Shareholders
- 77
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 18,798,156
- Address
- 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE, 22901
- Web
- https://www.adialpharma.com/
- Phone
- +1 4344229800
- Contact
- David Waldman
- Auditors
- Friedman LLP
Latest News for ADIL
Upcoming events for ADIL
Similar to ADIL
180 LIFE SCIENCES ORD
NASDAQ Capital Market
9 METERS BIOPHARMA ORD
NASDAQ Capital Market
ABVC BIOPHARMA ORD
NASDAQ Capital Market
ACER THERAPEUTICS ORD
NASDAQ Capital Market
ADITXT ORD
NASDAQ Capital Market
FAQ
As of Today at 19:56 UTC, shares in Adial Pharmaceuticals are trading at $3.29. This share price information is delayed by 15 minutes.
Shares in Adial Pharmaceuticals last closed at $3.29 and the price had moved by +113.64% over the past 365 days. In terms of relative price strength the Adial Pharmaceuticals share price has outperformed the S&P500 Index by +62.08% over the past year.
The overall consensus recommendation for Adial Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Adial Pharmaceuticals does not currently pay a dividend.
Adial Pharmaceuticals does not currently pay a dividend.
Adial Pharmaceuticals does not currently pay a dividend.
To buy shares in Adial Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.29, shares in Adial Pharmaceuticals had a market capitalisation of $61.85m.
Here are the trading details for Adial Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ADIL
Based on an overall assessment of its quality, value and momentum Adial Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Adial Pharmaceuticals is $5.00. That is 51.98% above the last closing price of $3.29.
Analysts covering Adial Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.87 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adial Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -2.81%.
As of the last closing price of $3.29, shares in Adial Pharmaceuticals were trading +40.37% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Adial Pharmaceuticals.
Adial Pharmaceuticals' management team is headed by:
- William Stilley - PRE
- Kevin Schuyler -
- Joseph Truluck - CFO
- Bankole Johnson - OTH
- J. Kermit Anderson -
- Robertson Gilliland -
- Tony Goodman -
- James Newman -
We do not have data on Adial Pharmaceuticals' shareholders